Quantum-Si Introduces Protein Barcoding Kit for Multiplexed Protein Screening
Quantum-Si (Nasdaq: QSI) has launched its new protein Barcoding Kit, designed to revolutionize protein research through multiplexed screening. The kit employs peptide barcodes for efficient protein analysis, particularly beneficial for biopharma research applications including lipid nanoparticle optimization and mRNA therapeutics evaluation. Key features include overnight workflow with minimal hands-on time, ability to detect low-abundance proteins, and relative quantitation across a broad dynamic range. The solution aims to reduce time and costs while maintaining high sensitivity for therapeutic development.
Quantum-Si (Nasdaq: QSI) ha lanciato il suo nuovo Barcoding Kit per le proteine, progettato per rivoluzionare la ricerca sulle proteine attraverso lo screening multiplexato. Il kit utilizza codici a barre peptidici per un'analisi efficace delle proteine, risultando particolarmente vantaggioso per le applicazioni di ricerca biopharma, tra cui l'ottimizzazione delle nanoparticelle lipidiche e la valutazione delle terapie a base di mRNA. Le caratteristiche principali includono un flusso di lavoro notturno con un tempo di intervento minimo, la capacità di rilevare proteine a bassa abbondanza e la quantificazione relativa su un ampio intervallo dinamico. La soluzione mira a ridurre tempo e costi mantenendo un'elevata sensibilità per lo sviluppo terapeutico.
Quantum-Si (Nasdaq: QSI) ha lanzado su nuevo Barcoding Kit de proteínas, diseñado para revolucionar la investigación proteica a través de la detección multiplexada. El kit emplea códigos de barras peptídicos para un análisis eficiente de proteínas, siendo especialmente beneficioso para aplicaciones de investigación biopharma, incluida la optimización de nanopartículas lipídicas y la evaluación de terapias con mRNA. Las características clave incluyen un flujo de trabajo nocturno con un tiempo de manejo mínimo, la capacidad de detectar proteínas de baja abundancia y la cuantificación relativa en un amplio rango dinámico. La solución busca reducir el tiempo y los costos mientras mantiene una alta sensibilidad para el desarrollo terapéutico.
Quantum-Si (Nasdaq: QSI)는 단백질 연구를 혁신하기 위해 설계된 새로운 바코드 키트를 출시했습니다. 이 키트는 다중검사를 통해 단백질 분석을 효율적으로 수행하기 위해 펩타이드 바코드를 사용합니다. 이는 지질 나노입자 최적화 및 mRNA 치료 평가를 포함한 생명공학 연구 애플리케이션에 특히 유익합니다. 주요 특징으로는 최소한의 작업 시간을 요구하는 야간 작업 흐름, 저농도 단백질 탐지 능력, 및 넓은 동적 범위에서의 상대 정량화가 포함됩니다. 이 솔루션은 높은 감도를 유지하면서 치료 개발을 위한 시간과 비용을 줄이는 것을 목표로 하고 있습니다.
Quantum-Si (Nasdaq: QSI) a lancé son nouveau Kit de Barcoding pour les protéines, conçu pour révolutionner la recherche sur les protéines grâce au criblage multiplement. Le kit utilise des codes-barres peptidiques pour une analyse protéique efficace, particulièrement bénéfique pour les applications de recherche biopharmaceutique, y compris l'optimisation des nanoparticules lipidiques et l'évaluation des thérapies basées sur l'ARNm. Les caractéristiques clés comprennent un flux de travail de nuit avec un temps d'intervention minimal, la capacité de détecter des protéines à faible abondance et la quantification relative sur une large plage dynamique. La solution vise à réduire le temps et les coûts tout en maintenant une haute sensibilité pour le développement thérapeutique.
Quantum-Si (Nasdaq: QSI) hat sein neues Barcoding Kit für Proteine eingeführt, das entwickelt wurde, um die Proteinforschung durch multiplexes Screening zu revolutionieren. Das Kit verwendet Peptid-Barcodes für eine effiziente Proteinanalyse und ist besonders vorteilhaft für biopharmazeutische Forschungsanwendungen, einschließlich der Optimierung von lipidbasierten Nanopartikeln und der Evaluierung von mRNA-Therapeutika. Zu den wichtigsten Funktionen gehören ein nächtlicher Arbeitsablauf mit minimalem Zeitaufwand, die Fähigkeit, Proteine mit niedriger Abundanz zu erkennen, und eine relative Quantifizierung über einen breiten dynamischen Bereich. Die Lösung zielt darauf ab, Zeit und Kosten zu reduzieren, während eine hohe Sensitivität für die therapeutische Entwicklung erhalten bleibt.
- Introduction of new product expanding company's portfolio
- Product offers time and cost efficiency benefits
- Technology addresses key biopharma research needs
- Solution provides broad dynamic range detection capability
- None.
Insights
The launch of QSI's protein Barcoding Kit represents a significant advancement in protein research technology, particularly for biopharma applications. The kit's key differentiators are its multiplexed screening capabilities and overnight workflow with minimal hands-on time, addressing major efficiency bottlenecks in therapeutic development.
The technology's ability to detect low-abundance proteins while providing relative quantitation across a broad dynamic range is particularly valuable for LNP optimization and mRNA therapeutic evaluation. This could accelerate drug development timelines and reduce costs for pharmaceutical companies. However, market adoption will depend on validation studies and competitive pricing against established protein analysis methods.
The protein Barcoding Kit offers a multiplexed solution for efficient protein screening using peptide barcodes, tailored to the needs of biopharma research. It supports critical applications such as optimizing lipid nanoparticle (LNP), evaluating mRNA therapeutics, and analyzing protein characteristics.
The kit reduces time and costs through streamlined workflows while delivering relative quantitation across a broad dynamic range. With an overnight workflow that requires less than an hour of hands-on time, it is designed to be sensitive enough to detect low-abundance proteins, providing researchers with an innovative tool for therapeutic development.
“We believe Quantum-Si’s protein Barcoding Kit represents a groundbreaking leap forward in protein research, combining multiplexed precision with effortless workflows to transform how biopharma tackles complex challenges. By enabling faster, more cost-effective analysis of protein and drug delivery systems, this innovation paves the way for breakthroughs in therapeutic development,” said Jeff Hawkins, President and Chief Executive Officer of Quantum-Si.
For more information about Quantum-Si’s innovative solutions, visit www.quantum-si.com.
About Quantum-Si Incorporated
Quantum-Si, The Protein Sequencing Company™, is focused on revolutionizing the growing field of proteomics. The Company’s Platinum® instrument enables Next-Gen Protein Sequencing™ that advances proteomic research, drug discovery, and diagnostics beyond what has been possible with existing proteomic tools. Learn more at quantum-si.com or follow us on LinkedIn or X.
Forward Looking Statements
This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. The actual results of the Company may differ from its expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company’s expectations with respect to future performance and development and commercialization of products and services. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside the Company’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the inability to maintain the listing of the Company’s Class A common stock on The Nasdaq Stock Market; the ability of the Company to grow and manage growth profitably and retain its key employees; the Company’s ongoing leadership transitions; changes in applicable laws or regulations; the ability of the Company to raise financing in the future; the success, cost and timing of the Company’s product development and commercialization activities; the commercialization and adoption of the Company’s existing products and the success of any product the Company may offer in the future; the potential attributes and benefits of the Company’s commercialized Platinum® protein sequencing instrument and kits and the Company’s other products once commercialized; the Company’s ability to obtain and maintain regulatory approval for its products, and any related restrictions and limitations of any approved product; the Company’s ability to identify, in-license or acquire additional technology; the Company’s ability to maintain its existing lease, license, manufacture and supply agreements; the Company’s ability to compete with other companies currently marketing or engaged in the development or commercialization of products and services that serve customers engaged in proteomic analysis, many of which have greater financial and marketing resources than the Company; the size and growth potential of the markets for the Company’s products and services, and its ability to serve those markets once commercialized, either alone or in partnership with others; the Company’s estimates regarding future expenses, future revenue, capital requirements and needs for additional financing; the Company’s financial performance; and other risks and uncertainties described under “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q and in the Company’s other filings with the SEC. The Company cautions that the foregoing list of factors is not exclusive. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241203384436/en/
Investor Contact
Jeff Keyes
Chief Financial Officer
ir@quantum-si.com
Media Contact
Katherine Atkinson, SVP, Commercial Marketing
media@quantum-si.com
Source: Quantum-Si Incorporated
FAQ
What is Quantum-Si's new Barcoding Kit used for?
What are the key features of QSI's protein Barcoding Kit?
How does the QSI Barcoding Kit improve protein research efficiency?
